alexa Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Pharmaceutical Sciences

Pharmaceutical Sciences

Journal of Bioequivalence & Bioavailability

Author(s): Edelman MJ, Meyers FJ, Houston J, Lauder I

Abstract Share this page

Abstract Advanced transitional cell carcinoma (TCC) of the urothelial tract is usually fatal despite high response rates to platinum-based chemotherapy regimens. Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated marked single-agent activity in TCC, and combinations of carboplatin and paclitaxel have been well tolerated in other solid tumors. Methotrexate is also active in TCC. Due to unexpectedly severe myelosuppression and mucositis when methotrexate and paclitaxel were combined, we undertook a phase I trial of paclitaxel, carboplatin, and escalating doses of methotrexate with granulocyte colony-stimulating factor and leucovorin support in advanced TCC to determine the feasibility of this combination. Nineteen previously untreated patients with locally advanced or metastatic TCC were eligible. Median age was 62 years. In sequence, paclitaxel 200 mg/m2 (3-hour infusion), carboplatin dosed to an area under the concentration-time curve of 6 mg/mL x min, and methotrexate 10 mg/m2, increasing in 10-mg/m2 increments, were administered on day 1 every 21 days. Granulocyte colony-stimulating factor 300 microg/d or 480 microg/d (in patients <60 kg or >60 kg, respectively) was administered on days 2 through 11 and leucovorin 15 mg orally every 6 hours for 3 days. At this time, the methotrexate dose has been escalated to 50 mg/m2. There were no dose-limiting toxicities in cycle 1. Sixty-eight cycles have been administered (range, one to eight cycles; median, three cycles). Significant hematologic toxicity including neutropenic sepsis (two episodes) occurred in subsequent cycles, but was infrequent. The major nonhematologic toxicity was neuropathy. Sixteen patients are evaluable for response. One patient has achieved a complete response, seven are partial responders, seven have stable disease, and one progressed on therapy. The overall response rate is 50\% (95\% confidence interval, 25\% to 75\%). The combination of paclitaxel, carboplatin, and methotrexate holds promise to be well tolerated and active in advanced TCC.
This article was published in Semin Oncol and referenced in Journal of Bioequivalence & Bioavailability

Relevant Expert PPTs

Relevant Speaker PPTs

  • Ensieh Shahvazian
    Resequencing of KLF14 gene in population based family study with type two diabetes
    PPT Version | PDF Version
  • Changchun Yang
    Feasibility study on DCA microspheres for deep profile control technology in high permeability of high temperature and high salt reservoirs
    PPT Version | PDF Version
  • Seema Narayan
    A comparative study of the link between real exchange rate of ASEAN countries and fossil fuel prices
    PDF Version
  • Navinchandra G. Ashar
    Comparative study of techno-economic evaluation of the production of liquid Sulphur Di Oxide
    PDF Version
  • Recep Çelik
    GIS based assessment effect of irrigation on groundwater level changes in agricultural areas: A case study on the Bismil plain in the Upper Tigris Basin
    PPT Version | PDF Version
  • Wondalem Misganaw Golie
    Adsorption equilibrium and kinetic study of removal of nitrate from drinking water supplies by chitosan composite
    PPT Version | PDF Version
  • Gunilla Lindqvist
    Chronic obstructive pulmonary disease: A study of the relationship between patients’ feeling of guilt due to their belief of the disease being self inflicted
    PDF Version
  • Rohit A
    Cardiovascular risk prediction using WHO/ISH chart in urban and rural subjects attending diabetes screening clinic: A pilot study
    PPT Version | PDF Version
  • Jahid Zeghiche
    Jahid-Zeghiche-Univesity-of-Al-Baha- Saudi-Arabia- Compressive- Strength-of-Concerete-filled-Thin- Steel-Stubs-Theoretical-and-Experimental-Study
    PPT Version | PDF Version
  • Won-SeokHeo
    PPT Version | PDF Version
  • Magdi A. Khalifa
    Magdi khalifa-Abu-Dhabi-United-Arab-Emirates-Structural-Steel-Connection-Design-between-the-Structural-Consultant-and-the-Steel-Fabricator
    PPT Version | PDF Version
  • Jonny Carlos da Silva
    PPT Version | PDF Version
  • Yi-Cheng Hu
    Detection of a negative correlation between prescription of Chinese herbal products containing coumestrol, genistein or daidzein and risk of subsequent endometrial cancer among tamoxifentreated female breast cancer survivors in Taiwan between 1998 and 2008: A population-based study
    PPT Version | PDF Version
  • Kamal M Bajoria
    Kamal Bajoria- Indian-Institute-of- Technology-Bombay-India- Performance-Based-Design-of-Cold-formed-Steel-Frames
    PPT Version | PDF Version
  • Carsten Worsoe
    The value of the “simulated study” as a tool to predict actual leachables in parenteral drug products
    PPT Version | PDF Version

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version